Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.

ABSTRACT:

Purpose

The phase III 22071-26071 trial was designed to evaluate the addition of panitumumab to adjuvant chemotherapy plus intensity modulated radiotherapy (IMRT) in locally advanced resected squamous cell head and neck cancer. We report the results of the dummy run (DR) performed to detect deviations from protocol guidelines.

Methods and materials

DR datasets consisting of target volumes, organs at risk (OAR) and treatment plans were digitally uploaded, then compared with reference contours and protocol guidelines by six central reviewers. Summary statistics and analyses of potential correlations between delineations and plan characteristics were performed.

Results

Of 23 datasets, 20 (87.0%) GTVs were evaluated as acceptable/borderline, along with 13 (56.5%) CTVs and

SUBMITTER: Fairchild A 

PROVIDER: S-EPMC4311463 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature